ArticleBMC public health2023
Cost-effectiveness analysis of sarcopenia management interventions in Iran.
Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Cost-effectiveness of opportunistic CT versus clinical methods for sarcopenia screening.Skeletal radiology · 2026Article
- Association between opium consumption and sarcopenia in middle-aged and older adults: findings from the Fasa Adults Cohort Study (FACS).Scientific reports · 2026Article
- Association between the digestion-resistant bioactive peptide content in dairy products and the risk of sarcopenia in Iranian elderly: a case-control study.Journal of health, population, and nutrition · 2025Article
- The relationship between elderly dietary index and sarcopenia: a case-control study.BMC geriatrics · 2025Article
- The proportion of moderate-to-vigorous-intensity physical activity to total volume of physical activity correlates with decreased risk of possible sarcopenia: A prospective cohort study.Journal of exercise science and fitness · 2025Article
- Article
- Economic burden of sarcopenia-related disability in the elderly population: a study in Iran.BMC research notes · 2024Article
- Skeletal Muscle Area on CT: Determination of an Optimal Height Scaling Power and Testing for Mortality Risk Prediction.AJR. American journal of roentgenology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIdentification the optimal management intervention of sarcopenia is a concern of health systems. We aimed to analyze the cost-effectiveness of sarcopenia management strategies in Iran.
methodsWe constructed a lifetime Markov model based on natural history. The strategies comparedincluded exercise training, nutritional supplements, whole body vibration (WBV), and various exercise interventions and nutritional supplement combinations. A total of 7 strategies was evaluated in addition to the non-intervention strategy. Parameter values were extracted from primary data and the literature, and the costs and Quality-adjusted life years (QALYs) were calculated for each strategy. Deterministic and probabilistic sensitivity analysis, including the expected value of perfect information (EVPI), was also performed to determine the robustness of the model. Analyses were performed using the 2020 version of TreeAge Pro software.
resultsAll seven strategies increased lifetime effectiveness (QALYs). The protein and Vitamin D
conclusionsStudy results, as the first economic evaluation of sarcopenia management interventions, showed that despite the higher effectiveness of D + P, the D strategy was the most cost-effective. Completing clinical evidence of various intervention options can lead to more accurate results in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.